Increased PSA after prostatectomy may not result in metastasis in some men's lifetime
the ONA take:
According to a new study published in the journal Clinical Cancer Research, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that some patients with prostate cancer whose prostate-specific antigen (PSA) levels become elevated after a radical prostatectomy may die as a result of a cause unrelated to prostate cancer before being diagnosed with cancer metastasis.
Therefore, active surveillance may be more beneficial than treating them for recurrence. For the study, the researchers analyzed data from various studies including patients with prostate cancer. Using this data, they created a simulation model to determine the number of patients with PSA recurrence who would die from unrelated causes in less time than it would take for PSA recurrence to cause metastasis in the absence of treatment.
They found that 9.1% and 15.6% of patients with prostate cancer whose PSA levels are elevated 5 years and 10 years after their initial treatment, respectively, may not experience metastatic disease before dying. Those patients are therefore overdetected for recurrence as the likelihood of recurrence before death is low. The simulation also found that 31.4% of men older than 70 with PSA recurrence within 10 years of initial diagnosis were overdetected.
Some patients whose PSA levels become elevated after prostatectomy may die of unrelated causes.
Some prostate cancer patients whose prostate-specific antigen (PSA) levels increase after a radical prostatectomy may die of causes unrelated to prostate cancer before they are diagnosed with a prostate cancer metastasis, and therefore treating them for recurrence may not be beneficial, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
"Previous studies have indicated that the interval from PSA recurrence to metastasis is quite long, with a median of more than eight years, even in the absence of any treatment for the recurrence," said Ruth Etzioni, PhD, full member of the Public Health Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, Washington. "Given that the majority of prostate cancer patients are older, we expect that many would die of other causes before reaching the point of metastasis.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|